STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics Form 4: Hopman Disposes 848 Shares to Cover Taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Mark Hopman, identified as the Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported a transaction on 09/02/2025. The filing shows 848 shares of Common Stock were sold to cover tax withholding obligations related to restricted stock unit vesting. The weighted average sale price was $18.8632, with individual sale prices ranging from $18.58 to $19.09. After the reported transaction, Hopman beneficially owned 33,284 shares directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Positive

  • Clear disclosure that the sale was to cover tax withholding associated with RSU vesting
  • Detailed pricing provided: weighted average $18.8632 and range $18.58–$19.09
  • Post-transaction ownership disclosed: 33,284 shares held directly

Negative

  • None.

Insights

TL;DR: Routine tax-withholding sale by an officer; limited market impact.

The transaction is a small, administrative sale—848 shares—executed to satisfy tax withholding for RSU vesting. The weighted average price of $18.8632 and the disclosed price range indicate the trades occurred within a narrow band, suggesting no large, market-moving disposition. Post-transaction ownership of 33,284 shares retains officer alignment with shareholders but does not signal a change in control or material shift in holdings.

TL;DR: Disclosure is standard and complies with Section 16 reporting conventions.

The Form 4 clearly states the sale was to cover tax withholding tied to RSU vesting, which is a common practice. The filing includes the weighted average sale price and price range and is signed by an authorized attorney-in-fact, reflecting appropriate procedural compliance. There is no indication of an agreement or Rule 10b5-1 plan in the disclosed fields.

Insider Hopman Mark
Role Chief Commercial Officer
Sold 848 shs ($16K)
Type Security Shares Price Value
Sale Common Stock 848 $18.8632 $16K
Holdings After Transaction: Common Stock — 33,284 shares (Direct)
Footnotes (2)
  1. F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
  2. F2. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

FAQ

What did Beta Bionics (BBNX) insider Mark Hopman report on Form 4?
He reported the sale of 848 shares on 09/02/2025, executed to cover tax withholding for RSU vesting.

At what price were the 848 shares sold in the Form 4 filed for BBNX?
The weighted average sale price was $18.8632, with individual prices ranging from $18.58 to $19.09.

How many BBNX shares did Mark Hopman own after the reported transaction?
Following the transaction, Hopman beneficially owned 33,284 shares directly.

Why were the BBNX shares sold according to the Form 4?
The filing states the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units.

Who signed the Form 4 reporting Mark Hopman's transaction for BBNX?
The Form 4 was signed by Stephen Feider, Attorney-in-Fact on 09/03/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hopman Mark
(Last) (First) (Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/02/2025 S(1) 848 D $18.8632(2) 33,284 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Stephen Feider, Attorney-in-Fact 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR